Sertoli-Cell-Only Syndrome & Maturation Arrest
Non-Obstructive Azoospermia Histology Patterns and MicroTESE Yields
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not applicable (histologic diagnosis)
Reference only. Not medical advice.
What can go wrong
MicroTESE risks include testicular devascularization, atrophy, hematoma, and transient testosterone decline; repeated procedures compound this. The emotional stakes are high - a failed retrieval can end the possibility of biological fatherhood. Pre-operative genetic testing (karyotype, Y-microdeletions) is essential both to guide prognosis and to counsel about transmissible conditions before ICSI.
This is something to take to a clinician. The Atlas can tell you what is known about sertoli-cell-only syndrome & maturation arrest in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Non-obstructive azoospermia (NOA) is subclassified by testicular histology, and the two named patterns here - Sertoli-cell-only syndrome (SCOS) and maturation arrest - together with severe hypospermatogenesis define the spectrum. In SCOS (Del Castillo syndrome), seminiferous tubules contain only Sertoli cells (and interstitial Leydig cells) with no germ cells; it is the most common NOA pattern (~44.8% in one series). Maturation arrest is germ-cell development halted at a specific stage. The histology is not academic: it sets the odds of finding sperm at microdissection testicular sperm extraction (microTESE), the only route to biological paternity for many of these men.
The empty tubules behind non-obstructive azoospermia - and why the histology sets the odds.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
In SCOS, seminiferous tubules lack the germ-cell lineage entirely - only Sertoli (support) and Leydig (hormone) cells remain - so no spermatogenesis occurs; causes range from congenital germ-cell absence to Y-chromosome AZF microdeletions, prior insults (chemotherapy, radiation, mumps orchitis, torsion), or idiopathic. In maturation arrest, germ cells are present but development halts at spermatogonial, spermatocyte, or spermatid stages, often with a genetic or meiotic basis. Both can be focal rather than uniform, which is precisely why microTESE - searching for rare pockets of spermatogenesis under the operating microscope - can succeed where random biopsy fails.
The catch: the biopsy label predicts odds, but focal disease keeps hope
The clinical power of the histology is prognostic. Retrieval odds rise steeply with the pattern: hypospermatogenesis yields sperm in the vast majority (~95%), maturation arrest in roughly half to two-thirds (~58%), and SCOS lowest (commonly ~22-41% for pure SCOS, higher in mixed series). But because damage is often patchy, even a SCOS biopsy report is not a verdict - microTESE can still find focal spermatogenesis. Genetic context matters: complete AZFa or AZFb deletions predict essentially zero retrieval, sparing men a futile operation, while AZFc deletions carry a reasonable chance.
When this is an emergency
Azoospermia confirmed on repeated centrifuged samples with normal FSH pointing toward obstruction and elevated FSH/small testes toward NOA. Definitive subclassification (SCOS vs maturation arrest vs hypospermatogenesis) requires testicular histology, ideally obtained at the time of microTESE. Karyotype and Y-chromosome microdeletion testing are standard before retrieval.
What it does to fertility
This entry is the histologic engine of NOA fertility prognosis. The pattern directly predicts microTESE success and thus whether ICSI with the man's own sperm is possible. Genetic testing refines this and prevents futile surgery. For men in whom retrieval fails, the histology also frames honest counseling toward donor sperm or adoption. It deepens the general azoospermia overview by centering the biopsy patterns and their quantified retrieval odds.
What people get wrong
Often saidA Sertoli-cell-only diagnosis means no chance of biological children
ActuallyNot necessarily - disease is often focal, and microTESE finds sperm in a meaningful minority of pure SCOS cases (and more in mixed patterns), enabling ICSI.
Often saidAll non-obstructive azoospermia is the same
ActuallyRetrieval odds differ dramatically by histology and genetics, from ~95% in hypospermatogenesis down to low rates in pure SCOS, and near-zero with complete AZFa/AZFb deletions.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
The people taking it
Men with non-obstructive azoospermia presenting for infertility - including those with genetic causes (Y-microdeletions, Klinefelter), prior gonadotoxic exposure (chemo/radiation), or idiopathic disease.
What we do not know
- Can non-invasive biomarkers predict focal spermatogenesis and spare futile microTESE?
- Will in-vitro spermatogenesis or germline approaches ever help men with true, complete SCOS?
At a glance
- SCOS frequency in NOA
- Most common pattern (~44.8% in one series)
- SCOS microTESE retrieval
- ~22.5-56% (lowest across patterns; often cited ~22.5-41% for pure SCOS)
- Maturation arrest retrieval
- ~58.5% in one subgroup analysis
- Hypospermatogenesis retrieval
- ~95.6% (highest)
- Diagnosis
- Requires testicular biopsy/histology
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Sertoli-Cell-Only Syndrome & Maturation Arrest. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Sertoli Cell-Only Syndrome (StatPearls)2018 (ongoing)
Defines SCOS histology, etiologies, and retrieval prognosis
Subgroup microTESE outcome analyses by histologyvarious
Retrieval ~95.6% hypospermatogenesis, ~58.5% maturation arrest, ~56% (to ~22.5% for pure) SCOS
Studies of Sertoli/germ cells within atrophic tubules in NOA2022
Focal residual spermatogenesis can exist within apparently barren tubules